MAY 30, 2018 2:00 AM PDT

Antibody Offers New Hope For Celiac Disease Patients

WRITTEN BY: Nouran Amin

Celiac disease is genetically predisposed to hereditary disease and a serious autoimmune disorder that can damage the small intestine upon the ingestion of gluten. Roughly 1 in 100 people are affected worldwide and about two and one-half million Americans are undiagnosed or are at risk for long-term health complications.

When individuals with celiac disease ingest gluten (a protein found in wheat, rye, and barley), their body produces an immune response that attacks the small intestine; leading to damage of the villi where nutrients cannot be absorbed properly. As of now, the only treatment for celiac disease is avoiding any gluten-contained foods; strictly gluten-free diet. Individuals with celiac disease must avoid foods with wheat, rye, and barley, such as bread and beer. Sometimes, these individuals might accidentally ingest small amounts of gluten which unfortunately can trigger small intestine damage.

Now, investigators have found an antibody by the name of AMG 714 may reduce symptoms of gluten exposure. AMG 174 works to inhibit interleukin-15, a crucial mediator of celiac disease. "It's important to note that this drug is being investigated for its potential to protect against modest contamination, not deliberately eating large amounts of gluten, like bread or pasta," said Francisco Leon, MD, PhD, the study director and consultant for Amgen. "Contamination, which can happen during food processing or packaging, during cooking, or due to inadequate labeling, is known to occur very frequently, despite following a gluten-free diet. Our hope is that this drug may allow celiac patients on a gluten-free diet to experience fewer gluten-triggered events."

Image via The Mayo Clinic

Results of the research study showed that the antibody, AMG 714, decreased gluten-triggered effects of celiac patients that were administered the drug in comparison to a placebo. Although AMG 714 did not completely prevent gluten-induced mucosal injury in patients of the “gluten challenge group”, the main endpoint of this study, a reduction in intestinal inflammation was examined, as well as a non-significant trend towards decreased intestinal damage in patients of the “non-challenge group”. A decrease in symptoms was observed when patient-reported outcomes were examined, especially for patients that took a larger drug dose of 300. While the placebo group had an increase in diarrhea, these symptoms were not apparent in patients who took the drug. By week 12, not a single patient administered the 300 mg dose was declared by the principal investigator to have active disease, compared to only one-third of the patients in the placebo group. For the group that did not receive the gluten challenge, there were no symptoms that were evident to be associated with accidental gluten consumption. Most importantly, no serious adverse events or noted dangers were seen in the study. Most complications that were reported included the study drug injection site reactions and pain. Headaches and upper respiratory tract infections were also reported. Additionally, dose-related trends were not evident with the exception of injection site reactions. "A gluten-free diet has been the only treatment option for celiac disease patients to date, yet it is nearly impossible for them to avoid gluten entirely and indefinitely," said Markku Maki, MD, PhD, the principal investigator and a professor for the Faculty of Medicine and Biosciences at the University of Tampere in Finland. "An average of half of all celiac disease patients on a gluten-free diet continue to have mucosal inflammation or damage, and a third have recurrent symptoms. That is why we have been investigating medications to help prevent the consequences of hidden gluten.

 

Source: Digestive Disease Week

 

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JUN 10, 2020
Drug Discovery & Development
FDA Approves New Antibiotic for Hospital-Acquired Pneumonia
JUN 10, 2020
FDA Approves New Antibiotic for Hospital-Acquired Pneumonia
The US Food and Drug Administration (FDA) has approved Recarbrio, an antibiotic drug created by pharmaceutical company M ...
JUN 11, 2020
Cancer
Fighting Cancer Stem Cells with Combination Therapy
JUN 11, 2020
Fighting Cancer Stem Cells with Combination Therapy
Pancreatic cancer is one of the most fatal cancers in the United States and is rapidly advancing up the ranks. The best ...
JUN 23, 2020
Drug Discovery & Development
Psychedelic DMT to Enter Clinical Trials
JUN 23, 2020
Psychedelic DMT to Enter Clinical Trials
Neuro-pharmaceutical company, MindMed, has announced that it will begin a double-blind placebo-controlled Phase 1 clinic ...
JUL 07, 2020
Immunology
Existing drugs can prevent SARS-CoV-2 from hijacking cells
JUL 07, 2020
Existing drugs can prevent SARS-CoV-2 from hijacking cells
An international team of researchers has analysed how SARS-CoV-2, the virus that causes COVID-19, hijacks the proteins i ...
JUL 26, 2020
Cannabis Sciences
Medicinal Cannabis Kills Cancer Cells
JUL 26, 2020
Medicinal Cannabis Kills Cancer Cells
Researchers at the University of Newcastle have found that a modified version of medicinal cannabis can kill and inhibit ...
JUL 24, 2020
Drug Discovery & Development
Profiling Technology Provides Rapid Drug Discovery
JUL 24, 2020
Profiling Technology Provides Rapid Drug Discovery
Rapid drug discovery saves lives and new technology is aiming to do just that in the fight against tuberculosis. Learn m ...
Loading Comments...